Pharma 4.0 Market

Pharma 4.0 Market (Technology: Artificial Intelligence [AI], Big Data Analytics, Cloud Computing, Internet of Things [IoT], and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Pharma 4.0 Market Outlook 2031

  • The global industry was valued at US$ 10.9 Bn in 2022
  • It is projected to grow at a CAGR of 17.7% from 2023 to 2031 and reach more than US$ 46.9 Bn by the end of 2031

Analysts’ Viewpoint

Increase in demand for personalized medicine and development of more targeted and effective treatments are key market drivers. Rise in regulatory pressure to improve the quality and safety of drug products is also fueling market dynamics. Furthermore, surge in adoption of digital technologies is anticipated to boost the global pharma 4.0 market size during the forecast period. Artificial intelligence (AI) and machine learning (ML) are increasingly being adopted to identify and validate potential drug targets. These technologies are accelerating the drug discovery process, thereby augmenting market statistics.

Collaborations between pharmaceutical and technology companies are creating lucrative pharma 4.0 market opportunities for industry players. However, complex regulatory environment, limited access to healthcare facilities in developing countries, and resistance to change and adoption of new technologies are hampering market growth.

Pharma 4.0

Market Introduction

The pharmaceutical sector is moving toward integration of recent technological developments in digitization and industry 4.0 practices into the drug manufacturing process. 'Pharma 4.0' is the name given to this integration. Creation of digital twins of production lines is an essential part of this integration.

Industry 4.0-related smart technologies, such as Big Data Analytics (BDA), Internet of Things (IoT), Cyber-Physical Systems (CPS), and Cloud Computing (CC), are essential in fostering the shift from conventional manufacturing to smart manufacturing.

Numerous manufacturing tasks, including remote sensing, process visualization, real-time data acquisition and monitoring, and control of all devices across a manufacturing network, are becoming more practical with the development of these industry 4.0 technologies.

Companies are focusing on smart manufacturing in the pharmaceutical sector by adopting pharma 4.0 technologies. Connected pharmaceutical manufacturing tools are also being used across the globe.

Increase in Focus on Operational Efficiency and Reducing Production Costs

The pharmaceutical sector is under pressure to improve operational efficiency and reduce production costs. This can be ascribed to the rise in need to bring drugs to market faster, growth in competition from generic drugs, and increase in cost of healthcare. Therefore, pharmaceutical companies are turning toward pharma 4.0 solutions to streamline operations, reduce costs, and improve productivity.

Pharma 4.0 solutions are driving operational efficiency by enabling pharmaceutical companies to optimize supply chain management. Pharmaceutical companies can track products throughout the supply chain, from raw materials to finished products, with the help of IoT sensors and other connected devices. This enables them to identify bottlenecks and inefficiencies in the production process, and take corrective actions to improve efficiency and reduce costs.

Pharma 4.0 solutions are also being adopted to improve the efficiency of drug development and clinical trials. Pharmaceutical companies can analyze large amounts of data to identify potential drug candidates and optimize clinical trial design by leveraging big data analytics and AI. This can enable them to bring drugs to market faster and at a lower cost, while also improving patient outcomes.

Pharmaceutical companies can also reduce the need for manual labor and improve accuracy and consistency of manufacturing processes by adopting advanced robotics and other automation technologies. This can lead to a significant decrease in production costs, while improving product quality and consistency.

Growth in Adoption of Advanced Technologies in Pharmaceutical Sector Augmenting Pharma 4.0 Market Demand

Artificial intelligence (AI), Big Data Analytics, and Internet of Things (IoT) are gaining traction in the pharmaceutical sector. These technologies help enhance drug manufacturing processes.

Increase in usage of AI and big data analytics in drug discovery and development is one of the key drivers of the pharma 4.0 market. AI can be used to analyze large amounts of data, such as genomic data and clinical trial data, in order to identify potential drug candidates and optimize clinical trial design.

Growth in adoption of IoT devices in manufacturing and supply chain management is another key driver of the global market. IoT devices can be used to monitor the manufacturing process, track drug shipments, and monitor patient health. This data can be used to improve quality control, optimize supply chain management, and personalize treatments.

High Demand for Cloud-based Solutions in Pharmaceutical Sector

Cloud computing is a key technology that supports the implementation of digital tools and facilitates their integration and scalability in the pharmaceutical sector.

Cloud computing allows pharmaceutical companies to store and process large amounts of data securely and efficiently, without the need for expensive on-premise hardware. It also enables remote access to data and applications, which can improve collaboration and productivity across different departments, teams, and locations.

Cloud computing technology enables pharmaceutical companies to leverage the power of digital technologies in a flexible, scalable, and cost-effective manner. Pharmaceutical companies can accelerate innovation, improve patient outcomes, and enhance competitiveness in a rapidly evolving market by adopting cloud-based solutions.

Rise in Application of Pharma 4.0 in Drug Discovery and Development

As per the pharma 4.0 market research report, the drug discovery and development application segment is anticipated to lead the global landscape during the forecast period. Applications of industry 4.0 in the pharmaceutical industry are rising across the globe.

Pharma 4.0 refers to digital transformation in pharmaceuticals through the integration of advanced technologies. These advanced technologies improve the efficiency and effectiveness of the drug discovery and development process by reducing costs and improving patient outcomes.

Drug discovery and development process involves the adoption of data analytics to identify promising drug targets, predict potential drug interactions and side effects, and optimize drug efficacy and dosing. Thus, increase in usage of pharma 4.0 in drug development and discovery is fueling market progress.

Surge in Adoption of Pharma 4.0 Among Pharmaceutical Companies

The pharmaceutical companies end-user segment is estimated to account for major share of the global landscape during the forecast period. Pharma 4.0 refers to the fourth industrial revolution in the pharmaceutical sector, which is characterized by the integration of advanced digital technologies into drug development and manufacturing processes.

Pharmaceutical companies are increasingly adopting pharma 4.0 technologies to improve efficiency, quality, and safety of drug development and manufacturing. These technologies can help pharmaceutical companies optimize their manufacturing processes and accelerate drug development timelines.

The pharmaceutical sector is highly regulated, and pharma 4.0 technologies can help companies comply with regulatory requirements by providing real-time monitoring and control of manufacturing processes as well as end-to-end traceability of drug products.

Regional Outlook of Pharma 4.0 Industry

According to the latest pharma 4.0 market forecast, North America is expected to account for significant share during the forecast period. Presence of well-established healthcare infrastructure and pharmaceutical sector, and strong focus on research and development are augmenting the market in the region.

Increase in adoption of digital technologies in the pharmaceutical sector and rise in government initiatives to promote the adoption of pharma 4.0 technologies are also fueling pharma 4.0 market growth in North America. Furthermore, growth in the trend of digitalization in the pharmaceutical sector is likely to propel pharma 4.0 market development in the region.

Analysis of Key Players

The global landscape is fragmented, with the presence of a few key players that control majority of the pharma 4.0 market share. Leading players are implementing various strategies, such as expansion of product portfolio, mergers, acquisitions, and partnerships, to strengthen their market position.

Some of the prominent pharma 4.0 companies operating across the globe are Siemens Healthcare GmbH, GE Healthcare, IBM Corporation, Amazon Web Services, Inc., Microsoft Corporation, Oracle Corporation, ABB, Honeywell International Inc., and Cisco Systems, Inc. These players are following the latest pharma 4.0 market trends to avail lucrative revenue opportunities.

Key Developments in Pharma 4.0 Market

  • In March 2022, Microsoft Corporation announced the acquisition of Nuance Communications to expand its capabilities in the healthcare sector. The acquisition is aimed at enhancing Microsoft's AI and cloud offerings for healthcare providers and accelerating the delivery of new solutions for clinical documentation, patient engagement, and other healthcare scenarios.
  • In 2021, Amazon Web Services, Inc. announced a partnership with Novartis, a Switzerland-based pharmaceutical company, to develop and deploy AI and machine learning solutions for drug discovery and development
  • In 2020, Amazon Web Services, Inc. announced a partnership with Moderna, a biotechnology company that develops mRNA-based vaccines and therapeutics, to support the development and manufacture of the former’s COVID-19 vaccine. Amazon Web Services, Inc. provided cloud computing, storage, and analytics services to help Moderna accelerate the development process.

The pharma 4.0 market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Market Snapshot

Attribute Detail

Market Value in 2022

US$ 10.9 Bn

Market Forecast Value in 2031

More than US$ 46.9 Bn

Growth Rate (CAGR)

17.7%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes global analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, porter’s five forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Technology
    • Artificial Intelligence (AI)
    • Big Data Analytics
    • Cloud Computing
    • Internet of Things (IoT)
    • Others
  • Application
    • Drug Discovery and Development
    • Clinical Trials
    • Manufacturing
    • Others
  • End-user
    • Pharmaceutical Companies
    • Biotechnology Companies
    • CROs and CMOs
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Siemens Healthcare GmbH
  • GE Healthcare
  • IBM Corporation
  • Amazon Web Services, Inc.
  • Microsoft Corporation
  • Oracle Corporation
  • ABB
  • Honeywell International Inc.
  • Cisco Systems, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global pharma 4.0 market in 2022?

It was valued at US$ 10.9 Bn in 2022

How big will the pharma 4.0 industry be in 2031?

It is projected to reach more than US$ 46.9 Bn by 2031

What will be the CAGR of the pharma 4.0 business during the forecast period (2023-2031)?

The CAGR is anticipated to be 17.7% during the forecast period

What are the prominent factors fueling the growth of the pharma 4.0 sector?

Increase in demand for personalized medicine, and rise in need for more efficient and cost-effective drug development and manufacturing processes

Which region is more attractive for pharma 4.0?

North America is a more attractive region

Who are the prominent pharma 4.0 companies?

Siemens Healthcare GmbH, GE Healthcare, IBM Corporation, Amazon Web Services, Inc., Microsoft Corporation, Oracle Corporation, ABB, Honeywell International Inc., and Cisco Systems, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Pharma 4.0 Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Pharma 4.0 Market Analysis and Forecast, 2017-2031

    5. Key Insights

        5.1. Porter’s Five Force Analysis

        5.2. Regulatory Scenario Pharma 4.0

        5.3. Technological Advancements: Pharmaceutical Manufacturing Processes

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Pharma 4.0 Market Analysis and Forecast, by Technology

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Technology, 2017-2031

            6.3.1. Artificial Intelligence (AI)

            6.3.2. Big Data Analytics

            6.3.3. Cloud computing

            6.3.4. Internet of Things (IoT)

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Technology

    7. Global Pharma 4.0 Market Analysis and Forecast, by Application

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Application, 2017-2031

            7.3.1. Drug Discovery and Development

            7.3.2. Clinical Trials

            7.3.3. Manufacturing

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by Application

    8. Global Pharma 4.0 Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by End-user, 2017-2031

            8.3.1. Pharmaceutical Companies

            8.3.2. Biotechnology Companies

            8.3.3. CROs and CMOs

            8.3.4. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Pharma 4.0 Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017-2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Pharma 4.0 Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Technology, 2017-2031

            10.2.1. Artificial Intelligence (AI)

            10.2.2. Big Data Analytics

            10.2.3. Cloud computing

            10.2.4. Internet of Things (IoT)

            10.2.5. Others

        10.3. Market Value Forecast, by Application, 2017-2031

            10.3.1. Drug Discovery and Development

            10.3.2. Clinical Trials

            10.3.3. Manufacturing

            10.3.4. Others

        10.4. Market Value Forecast, by End-user, 2017-2031

            10.4.1. Pharmaceutical Companies

            10.4.2. Biotechnology Companies

            10.4.3. CROs and CMOs

            10.4.4. Others

        10.5. Market Value Forecast, by Country, 2017-2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Technology

            10.6.2. By Application

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Pharma 4.0 Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Technology, 2017-2031

            11.2.1. Artificial Intelligence (AI)

            11.2.2. Big Data Analytics

            11.2.3. Cloud computing

            11.2.4. Internet of Things (IoT)

            11.2.5. Others

        11.3. Market Value Forecast, by Application, 2017-2031

            11.3.1. Drug Discovery and Development

            11.3.2. Clinical Trials

            11.3.3. Manufacturing

            11.3.4. Others

        11.4. Market Value Forecast, by End-user, 2017-2031

            11.4.1. Pharmaceutical Companies

            11.4.2. Biotechnology Companies

            11.4.3. CROs and CMOs

            11.4.4. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Technology

            11.6.2. By Application

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Pharma 4.0 Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Technology, 2017-2031

            12.2.1. Artificial Intelligence (AI)

            12.2.2. Big Data Analytics

            12.2.3. Cloud computing

            12.2.4. Internet of Things (IoT)

            12.2.5. Others

        12.3. Market Value Forecast, by Application, 2017-2031

            12.3.1. Drug Discovery and Development

            12.3.2. Clinical Trials

            12.3.3. Manufacturing

            12.3.4. Others

        12.4. Market Value Forecast, by End-user, 2017-2031

            12.4.1. Pharmaceutical Companies

            12.4.2. Biotechnology Companies

            12.4.3. CROs and CMOs

            12.4.4. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Technology

            12.6.2. By Application

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Pharma 4.0 Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Technology, 2017-2031

            13.2.1. Artificial Intelligence (AI)

            13.2.2. Big Data Analytics

            13.2.3. Cloud computing

            13.2.4. Internet of Things (IoT)

            13.2.5. Others

        13.3. Market Value Forecast, by Application, 2017-2031

            13.3.1. Drug Discovery and Development

            13.3.2. Clinical Trials

            13.3.3. Manufacturing

            13.3.4. Others

        13.4. Market Value Forecast, by End-user, 2017-2031

            13.4.1. Pharmaceutical Companies

            13.4.2. Biotechnology Companies

            13.4.3. CROs and CMOs

            13.4.4. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Technology

            13.6.2. By Application

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Pharma 4.0 Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Technology, 2017-2031

            14.2.1. Artificial Intelligence (AI)

            14.2.2. Big Data Analytics

            14.2.3. Cloud computing

            14.2.4. Internet of Things (IoT)

            14.2.5. Others

        14.3. Market Value Forecast, by Application, 2017-2031

            14.3.1. Drug Discovery and Development

            14.3.2. Clinical Trials

            14.3.3. Manufacturing

            14.3.4. Others

        14.4. Market Value Forecast, by End-user, 2017-2031

            14.4.1. Pharmaceutical Companies

            14.4.2. Biotechnology Companies

            14.4.3. CROs and CMOs

            14.4.4. Others

        14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Technology

            14.6.2. By Application

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (By Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Amazon Web Services, Inc.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Type Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Siemens Healthineers

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Type Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. GE Healthcare

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Type Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. IBM Corporation

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Type Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Microsoft Corporation

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Type Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Oracle Corporation

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Type Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. ABB

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Type Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Honeywell International Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Type Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Cisco Systems, Inc.

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Type Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 02: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 03: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 04: Global Pharma 4.0 Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 05: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 06: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 07: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 08: North America Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 09: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 10: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 11: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 12: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 13: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 14: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 15: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 16: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 17: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 18: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 19: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 20: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    Table 21: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by Technology, 2017-2031

    Table 23: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 24: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, by End-user, 2017-2031

    List of Figures

    Figure 01: Global Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: Global Pharma 4.0 Market Value Share, by Technology, 2022

    Figure 03: Global Pharma 4.0 Market Value Share, by Application, 2022

    Figure 04: Global Pharma 4.0 Market Value Share, by End-user, 2022

    Figure 05: Global Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 06: Global Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 07: Global Pharma 4.0 Market Revenue (US$ Mn), by Artificial Intelligence (AI), 2017-2031

    Figure 08: Global Pharma 4.0 Market Revenue (US$ Mn), by Big Data Analytics, 2017-2031

    Figure 09: Global Pharma 4.0 Market Revenue (US$ Mn), by Cloud Computing, 2017-2031

    Figure 10: Global Pharma 4.0 Market Revenue (US$ Mn), by Internet of Things (IoT), 2017-2031

    Figure 11: Global Pharma 4.0 Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 12: Global Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031

    Figure 13: Global Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031

    Figure 14: Global Pharma 4.0 Market Revenue (US$ Mn), by Drug Discovery and Development, 2017-2031

    Figure 15: Global Pharma 4.0 Market Revenue (US$ Mn), by Clinical Trials, 2017-2031

    Figure 16: Global Pharma 4.0 Market Revenue (US$ Mn), by Manufacturing, 2017-2031

    Figure 17: Global Pharma 4.0 Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 18: Global Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 19: Global Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 20: Global Pharma 4.0 Market Revenue (US$ Mn), by Pharmaceutical Companies, 2017-2031

    Figure 21: Global Pharma 4.0 Market Revenue (US$ Mn), by Biotechnology Companies, 2017-2031

    Figure 22: Global Pharma 4.0 Market Revenue (US$ Mn), by CROs and CMOs, 2017-2031

    Figure 23: Global Pharma 4.0 Market Revenue (US$ Mn), by Others, 2017-2031

    Figure 24: Global Pharma 4.0 Market Value Share Analysis, by Region, 2022 and 2031

    Figure 25: Global Pharma 4.0 Market Attractiveness Analysis, by Region, 2023-2031

    Figure 26: North America Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031

    Figure 27: North America Pharma 4.0 Market Value Share Analysis, by Country, 2022 and 2031

    Figure 28: North America Pharma 4.0 Market Attractiveness Analysis, by Country, 2023-2031

    Figure 29: North America Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 30: North America Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 31: North America Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031

    Figure 32: North America Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031

    Figure 33: North America Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 34: North America Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 35: Europe Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031

    Figure 36: Europe Pharma 4.0 Market Value Share Analysis, by Country, 2022 and 2031

    Figure 37: Europe Pharma 4.0 Market Attractiveness Analysis, by Country, 2023-2031

    Figure 38: Europe Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 39: Europe Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 40: Europe Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031

    Figure 41: Europe Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031

    Figure 42: Europe Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 43: Europe Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 44: Asia Pacific Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031

    Figure 45: Asia Pacific Pharma 4.0 Market Value Share Analysis, by Country, 2022 and 2031

    Figure 46: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by Country, 2023-2031

    Figure 47: Asia Pacific Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 48: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 49: Asia Pacific Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031

    Figure 50: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031

    Figure 51: Asia Pacific Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 52: Asia Pacific Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 53: Latin America Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031

    Figure 54: Latin America Pharma 4.0 Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 55: Latin America Pharma 4.0 Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 56: Latin America Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 57: Latin America Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 58: Latin America Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031

    Figure 59: Latin America Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031

    Figure 60: Latin America Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 61: Latin America Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031

    Figure 62: Middle East & Africa Pharma 4.0 Market Value (US$ Mn) Forecast, 2017-2031

    Figure 63: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 64: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 65: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by Technology, 2022 and 2031

    Figure 66: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by Technology, 2023-2031

    Figure 67: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by Application, 2022 and 2031

    Figure 68: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by Application, 2023-2031

    Figure 69: Middle East & Africa Pharma 4.0 Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 70: Middle East & Africa Pharma 4.0 Market Attractiveness Analysis, by End-user, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved